Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Growth Factors and Their Impact on Transfusion Medicine

Growth Factors and Their Impact on Transfusion Medicine Hematopoietic growth factors, glycoproteins that stimulate self-renewal, differentiation,and proliferation of responsive hematopoietic cells, promise to revolutionizetransfusion medicine. Recombinant DNA technology has made several ofthese cytokines available at pharmacologic doses, and new candidate agents forclinical application appear regularly. Growth factors prescribed for patients havealready reduced the requirement for red blood cell and granulocyte transfusionsin selected clinical circumstances. A lineage-specific thrombopoietin will likelylimit the need for platelet transfusions. Hematopoietic cytokine injections havealso been used to increase the number of red blood cells, granulocytes and circulatingprimitive progenitor cells in blood donors. Cytokine-stimulated peripheralblood progenitor cell infusions have complemented and, in some instances, replacedbone marrow for adjunctive cancer chemotherapy and for bone marrowtransplantation. Finally, synergistic combinations of cytokines can effect ex vivoexpansion of lymphocytes and of progenitor cells to provide novel blood components.Hematopoietic growth factors are still expensive and their long-term effectsremain to be determined. However, as the biologic activities of cytokinesand the physiology of hematopoietic progenitor cells become better understood,the clinical application of novel cellular components may redefine the concept ofblood transfusion. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Vox Sanguinis Karger

Growth Factors and Their Impact on Transfusion Medicine

Miller, Yvette M.; Klein, Harvey G.
Vox Sanguinis , Volume 71 (4): 9 – Jan 1, 2017
Download PDF
9 pages

Loading next page...
 
/lp/karger/growth-factors-and-their-impact-on-transfusion-medicine-atMuu5nyUW

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Karger
Copyright
© 1996 S. Karger AG, Basel
ISSN
0042-9007
eISSN
1423-0410
DOI
10.1159/000462058
Publisher site
See Article on Publisher Site

Abstract

Hematopoietic growth factors, glycoproteins that stimulate self-renewal, differentiation,and proliferation of responsive hematopoietic cells, promise to revolutionizetransfusion medicine. Recombinant DNA technology has made several ofthese cytokines available at pharmacologic doses, and new candidate agents forclinical application appear regularly. Growth factors prescribed for patients havealready reduced the requirement for red blood cell and granulocyte transfusionsin selected clinical circumstances. A lineage-specific thrombopoietin will likelylimit the need for platelet transfusions. Hematopoietic cytokine injections havealso been used to increase the number of red blood cells, granulocytes and circulatingprimitive progenitor cells in blood donors. Cytokine-stimulated peripheralblood progenitor cell infusions have complemented and, in some instances, replacedbone marrow for adjunctive cancer chemotherapy and for bone marrowtransplantation. Finally, synergistic combinations of cytokines can effect ex vivoexpansion of lymphocytes and of progenitor cells to provide novel blood components.Hematopoietic growth factors are still expensive and their long-term effectsremain to be determined. However, as the biologic activities of cytokinesand the physiology of hematopoietic progenitor cells become better understood,the clinical application of novel cellular components may redefine the concept ofblood transfusion.

Journal

Vox Sanguinis – Karger

Published: Jan 1, 2017

There are no references for this article.